US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% META $630.56 ▼-1.88% NVDA $216.00 ▲+2.39% AAPL $343.91 ▼-1.10% SPCX $146.90 ▼-0.40% MSFT $532.60 ▲+1.54% AMD $531.28 ▲+2.80%
FinancialContent

Certara, Inc. - Common Stock (NQ:CERT)

10.61 +0.28 (+2.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Certara, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
From Certara
Via GlobeNewswire
News headline image
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Issued on behalf of MindWalk Holdings Corp. 
From Market Updates
Via GlobeNewswire
News headline image
Certara Reports Second Quarter 2026 Financial Results
From Certara
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
From Certara
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences 
From Certara
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Certara Announces CFO Transition
Reaffirms 2026 Guidance 
From Certara
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
From Pomerantz LLP
Via GlobeNewswire
News headline image
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
CERTARA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Certara, Inc. on Behalf of Certara Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CERTARA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
Certara Reports First Quarter 2026 Financial Results
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business 
From Certara
Via GlobeNewswire
News headline image
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
From Altasciences
Via Business Wire
News headline image
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
From Certara
Via GlobeNewswire
News headline image
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
From Certara
Via GlobeNewswire
News headline image
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
From Certara
Via GlobeNewswire
News headline image
Healthcare AI Exits Pilot Phase, Enters Production Deployment
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
< Previous 1 2 3 4 Next >